According to the 2021 American College of Physicians and Infectious Diseases Society of America/European Society for Microbiology and Infectious Diseases guidelines, short-course antibiotic therapy is recommended for uncomplicated cystitis, with the duration determined by the antimicrobial agent used. The American College of Physicians guidance notes that although most patients with these infections are managed in the outpatient setting, the best practice advice statements also apply to patients who present in the inpatient setting. Recommended regimens include trimethoprim–sulfamethoxazole for 3 days, nitrofurantoin for 5 days, or fosfomycin as a single dose. These recommendations are based on clinical trial data demonstrating that short courses provide similar clinical cure rates to longer regimens while reducing unnecessary antibiotic exposure. Fluoroquinolones are also highly effective in 3-day regimens but are generally reserved as alternative agents because of adverse effects and risk of collateral damage, while β-lactam agents may be used for 3–7 days when preferred therapies are not appropriate, though they are generally considered less effective than first-line options. [1], [2]
A 2020 systematic review and network meta-analysis assessed the optimal duration of antibiotic regimens for acute uncomplicated cystitis in adult women. This comprehensive analysis included 61 randomized clinical trials encompassing a total of 20,780 participants. The primary outcome of interest was the clinical response, defined as the complete resolution of baseline symptoms at the test-of-cure visit. The findings indicated that single-dose regimens of third and fourth-generation fluoroquinolones had a similar effectiveness in achieving clinical and microbial responses compared to the traditional 3-day regimens, supported by a moderate level of evidence. Conversely, for antibiotics such as second-generation fluoroquinolones and co-trimoxazole, single-dose treatments were found to be less effective than 3-day regimens. The analysis suggested that a 3-day regimen of nitrofurantoin might be as effective as a 5-day regimen, although the evidence quality was very low. Importantly, these findings highlight the potential for shorter antibiotic regimens to be considered in clinical practice, which could reduce antibiotic resistance, adverse events, and associated healthcare costs, although further research is needed for some antibiotics due to the low quality of evidence currently available. [3]
Evidence from a 2005 meta-analysis and a 2005 Cochrane review comparing three-day antibiotic therapy with longer regimens (five days or more) for uncomplicated cystitis in non-pregnant women found largely similar conclusions. Across 32 randomized controlled trials including 9,605 patients, three-day regimens achieved symptomatic cure rates comparable to longer courses in both short- and long-term follow-up. However, shorter therapy was associated with higher rates of bacteriological failure, indicating less reliable eradication of bacteriuria compared with five- to ten-day regimens. This difference was particularly evident in trials where the same antibiotic was used for both durations and became more pronounced over longer follow-up. Despite this, adverse effects were reported more frequently with longer courses of therapy. Overall, these findings suggest that while three-day antibiotic regimens provide similar symptomatic relief to longer treatment durations, extended therapy may be more effective when complete bacteriological eradication is desired; although the evidence was not specific to hospitalized populations, it provides comparative data on treatment duration for uncomplicated cystitis. [4], [5]